Shire plc Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
11/16/2009 11:26:25 AM
More...
|
Shire plc Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules
11/11/2009 8:30:52 AM
More...
|
Shire plc: Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
11/9/2009 8:33:54 AM
More...
|
Shire plc Extends Agreement with Medidata Solutions, Inc. for Trial Planning Products
11/4/2009 9:24:14 AM
More...
|
FDA Grants Priority Review for Shire plc's (JOBS) Velaglucerase Alfa for Type 1 Gaucher Disease; PDUFA Date is February 28, 2010
11/4/2009 6:29:56 AM
More...
|
New Shire plc Board Member
11/2/2009 8:54:43 AM
More...
|
Shire plc Reports Tolerability and Clinical Effects Results of Daytrana(R)
11/2/2009 8:38:00 AM
More...
|
Shire plc to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
10/30/2009 9:05:12 AM
More...
|
Shire plc Continues to Deliver Excellent Growth From Core Products
10/30/2009 8:23:22 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) (JOBS) Reacquires Global Development and Commercialization Rights to Amigal(TM), Plicera(TM) and AT2220 Through a Mutual Termination Agreement with Shire plc (JOBS); Company to Cut 20 Percent Jobs; Announces Third Quarter 2009 Financial Results
10/30/2009 8:14:30 AM
More...
|
|